Literature DB >> 11286829

Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment.

L Miszczyk1, J Wydmański, J Spindel.   

Abstract

PURPOSE: The aim of this paper is to evaluate efficacy of radiotherapy for giant cell tumor of bone given either postoperatively or as sole treatment, and to assess prognostic factors for treatment outcome. METHODS AND MATERIALS: The study includes 37 patients. In 9 cases, soft tissue involvement was noted. Nonradical operation followed by radiotherapy was given to 23 patients, and 14 patients received irradiation only. Total dose of 39--64 Gy was delivered. The average follow-up was 5 years. Probability of local tumor control (LTC) depending on the treatment strategy was calculated, and prognostic factors were assessed.
RESULTS: LTC was noted in 31 cases. Ten-year LTC for surgery with irradiation was 83% and 69% for radiotherapy alone; however, this difference was not statistically significant. For tumors smaller than 4 cm LTC probability was above 90%, and it decreased to less than 60% for tumors larger than 8.5 cm. No dose-response relationship has been found. In 7 cases, late normal tissue effect occurred.
CONCLUSIONS: Giant cell tumors of bone can be considered as radiosensitive and radiotherapy with total dose of 40--45 Gy seems to be an effective sole treatment especially for tumors smaller than 4 cm in diameter. For larger tumors, surgery combined with postoperative radiotherapy should be considered.

Entities:  

Mesh:

Year:  2001        PMID: 11286829     DOI: 10.1016/s0360-3016(00)01520-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

Review 2.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

Review 3.  Giant cell tumour of bone: a new evaluating system is necessary.

Authors:  Han Wang; Ningjun Wan; Yongcheng Hu
Journal:  Int Orthop       Date:  2012-10-05       Impact factor: 3.075

4.  Aggressive clinical course of giant cell tumor arising from thoracic vertebra after a long latent period.

Authors:  Takeo Takahashi; Susumu Katano; Hitoshi Ishikawa; Takashi Nakano
Journal:  Radiat Med       Date:  2006-08

Review 5.  Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review.

Authors:  Yifei Ma; Wei Xu; Huabin Yin; Quan Huang; Tielong Liu; Xinghai Yang; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2015-05-06       Impact factor: 3.134

6.  Clival giant cell tumor presenting with isolated trigeminal nerve involvement.

Authors:  Soumyajit Roy; Nikhil P Joshi; Elanthenral Sigamani; Anita Malik; Meher C Sharma; Bidhu K Mohanti; Suresh C Sharma
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-10       Impact factor: 2.503

Review 7.  Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature.

Authors:  Falk Roeder; Carmen Timke; Felix Zwicker; Christian Thieke; Marc Bischof; Jürgen Debus; Peter E Huber
Journal:  Radiat Oncol       Date:  2010-02-26       Impact factor: 3.481

8.  Multiple giant cell tumors of bone arising from multiple fatty tumors.

Authors:  Alireza Eajazi; Arvin Kheterpal; Susan Kattapuram; Gunnlaugur Petur Nielsen; Daniel Ira Rosenthal
Journal:  Skeletal Radiol       Date:  2016-10-22       Impact factor: 2.199

9.  Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.

Authors:  Ping Jiang; Xile Zhang; Weijuan Jiang; Na Meng; Abudureyimujiang Aili; Junjie Wang
Journal:  Cancer Biol Ther       Date:  2020-04-16       Impact factor: 4.742

10.  The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).

Authors:  Jennifer L Beebe-Dimmer; Karynsa Cetin; Jon P Fryzek; Scott M Schuetze; Kendra Schwartz
Journal:  Rare Tumors       Date:  2009-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.